Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
Luca Richeldi(Coral Reef Alliance), Marlies Wijsenbeek(Erasmus University Rotterdam), Vincent Cottin(Université Claude Bernard Lyon 1), Arata Azuma(Nippon Medical School Hospital), Toby M. Maher(University of Southern California), Claudia Valenzuela(Hospital Universitario de La Princesa), Maud Gordat(Boehringer Ingelheim (France)), Donald F. Zoz(Boehringer Ingelheim (France)), Christina Schlecker(Boehringer Ingelheim (Germany)), Susanne Stowasser(Royal Brompton & Harefield NHS Foundation Trust), Yi Liu(WinnMed), Emmanuelle Clerisme-Beaty(Royal Brompton & Harefield NHS Foundation Trust), Fernando J. Martinez(UMass Memorial Health Care), Justin M. Oldham(Michigan Medicine), Michael Kreuter(Johannes Gutenberg University Mainz), Daniel Wachtlin(Boehringer Ingelheim (Germany))
Cited by 159
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
|European Respiratory Journal|2005|1k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953